XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
On May 27, 2026, FDA issued Warning Letter 320-26-80 to Pharmathen International S.A., a sterile drug product manufacturer located in Sapes, Rodopi Prefecture, Greece (Facility Establishment Identifier — FEI 3009961173). Following an inspection conducted
View details → On June 30, 2026, the Food and Drug Administration (FDA) classified a nationwide recall of prednisoLONE Acetate Ophthalmic Suspension, USP, 1%, manufactured by Lupin Limited at its Pithampur (Indore), Madhya Pradesh facility in India
View details →
Baxter International Inc. Recall — Cefazolin in Dextrose Injection: The Sterile Manufacturing System Failure Behind a Cardboard-Particulate Recall and What Every Fill-Finish Packaging Line Must Verify Now
View details → The FDA has classified a nationwide recall of eight Rohto Cooling Eye Drops products as Class II, covering 11,960,623 cartons — roughly 12.46 million bottles — sold at Walmart, CVS, Amazon, Kroger, and directly
View details → On August 4, 2026, Fresenius Kabi announced a voluntary nationwide recall to the user level of one lot of Morphine Sulfate Injection, USP, Simplist 2 mg/1 mL, after discovering that a MicroVault sealed and
View details → On August 5, 2026, Victory Medical Center Pharmacy of Austin, Texas, announced a voluntary nationwide recall to the patient level of certain lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials after pharmacy testing identified
View details →
On August 10, 2026, Fresenius Kabi announced a nationwide recall to the user level of one lot of Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL, after an internal investigation at the firm found the product
View details → On August 4, 2026, Novartis Pharmaceuticals Corporation initiated a recall of one lot of Diovan (valsartan) 160 mg tablets, 90-count bottles — lot AV5913C, expiration June 2027 — manufactured by Patheon Manufacturing Services LLC
View details → On August 5, 2026, Zydus Pharmaceuticals (USA) Inc. initiated a recall of one lot of Mirabegron Extended-Release Tablets, 25 mg, 30-count bottles — lot E408618, NDC 70710-1159-3, expiration November 30, 2026 — manufactured by
View details → On June 23, 2026, the Food and Drug Administration (FDA) classified Amgen Inc.'s recall of Corlanor (ivabradine) tablets — 5 mg and 7.5 mg, with 934,577 bottles of the 5 mg strength alone across
View details →XGene helps life-sciences teams identify where structured content and AI-assisted workflows can improve CMC traceability, reuse, review and decision support while preserving accountable human scientific and regulatory judgment.
View details →XGene evaluates contamination control across facility, people, process, utilities, materials, environmental monitoring, microbiology, interventions, validation and quality governance — then connects the findings to inspection readiness and sustainable remediation.
View details →Khaled Aamer, PhD, is the Founder and Principal Consultant of XGene Consulting, where he supports pharmaceutical and biotechnology organizations with FDA regulatory CMC strategy, GMP remediation, inspection readiness, data integrity, quality-system improvement, and CMC Module 3 development. His work connects scientific evidence, regulatory expectations, and operational execution across development, manufacturing, submission, and remediation programs. His […]
View details →The process begins with an initial consultation to clarify the problem, affected product or system, regulatory context, urgency, available evidence, and desired decision or deliverable. XGene then defines the scope, priorities, responsibilities, and review approach before moving into assessment or implementation. Work may include document and data review, gap assessment, risk prioritization, strategy development, drafting, […]
View details →XGene’s role can extend beyond document preparation. A strong regulatory response or CMC dossier depends on the quality of the underlying investigation, evidence, governance, and execution plan. Engagements may therefore include gap assessment, remediation architecture, CAPA strategy, quality-system review, data-integrity evaluation, batch-record review, supplier or CDMO oversight, stakeholder workshops, and follow-up verification in addition to […]
View details →The appropriate use depends on the level of regulatory maturity and human oversight. Established applications include tools supporting process monitoring, continued process verification, laboratory or manufacturing data management, and controlled electronic records. Emerging uses include AI-assisted Module 3 gap analysis, stability modeling, and batch-record review, provided outputs are verified by qualified personnel and the underlying […]
View details →A meeting is most useful when the sponsor can clearly define the decision needed, the evidence already available, the remaining uncertainty, and the consequence of proceeding without agency alignment. It should not substitute for completing analysis that the sponsor can reasonably perform internally. Before requesting a meeting, the team should identify the precise questions, evaluate […]
View details →XGene’s service scope is relevant to both development-stage sponsors and established pharmaceutical or life-sciences organizations. Early-stage companies may need help building an IND-ready CMC roadmap, identifying Module 3 gaps, defining control-strategy evidence, preparing for CDMO transfer, or establishing scalable quality practices. Established manufacturers may need targeted remediation, data-integrity assessment, inspection-response support, batch-record review, supplier oversight, […]
View details →